Skip to content
Recall Observatory FDA recall evidence

Drug product

MitoXANTRONE Injection, USP, (concentrate) 2 mg/mL, Rx Only. Hospira, Lake Forest, IL 60045, Product of Australia. Available in a) 20 mg/10 mL Multi Dose Vial (NDC: 61703-343-18); b) 25 mg/12.5 mL Multi Dose Vial (NDC: 61703-343-65); c) 30 mg/15 mL Multi Dose Vial (NDC: 61703-343-66).

D-0433-2015

December 03, 2014

Class I

Product summary

Firm
Hospira Inc.
Event
Event 70064
Status
Terminated
Classification
Class I
Quantity
13,792 Vials (U.S.)
Official record key
drug-enforcement:D-0433-2015

Official wording

Reason: Failed Stability Specifications: Product is subpotent and has out of specification known and unknown impurities.

Code information: LOTS DISTRIBUTED IN THE UNITED STATES: a) Lot: Z054636AA, Expiry: December 2014; Lot: A014636AA, Expiry: April 2015; Lot: A024636AB, Expiry: July 2015. b) Lot: A014645AA, Expiry: November 2015. c) Lot: A014643AA, Expiry April 2015.

Distribution pattern: US: Nationwide including Puerto Rico; Australia, Canada, Cyprus, Egypt, Ireland, Saudi Arabia, Qatar, Oman, Bahrain, and United Kingdom.

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    subpotent